Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 3 (abbreviated SERPINE3) is a protein-coding gene that encodes a putative serine protease inhibitor belonging to the serpin superfamily[4][3][2]. SERPINE3 is expressed specifically in the retinal pigment epithelium (RPE) in humans and is secreted in extracellular vesicles[1]. It is predicted to function as a serine-type endopeptidase inhibitor and may be involved in regulating proteolysis within the eye, stabilizing neuronal connections, or protecting neurons from proteolytic damage in the retina[1][3][4][5]. Protease inhibition screening suggests potential targets include caspases 1, 2, and 5, as well as cathepsin K[1]. Knockout of Serpine3 in mouse models leads to structural retinal abnormalities, indicating a critical role in retinal integrity and RPE function[1]. No direct drug interactions, clinical biomarkers, or established therapeutic mechanisms are currently known.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 3 (SERPINE3).